Holen Sie sich die Stockscreener-App
25.78
1.78%
0.45
Vorhandelsmarkt:
25.75
-0.03
-0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating - Yahoo Finance
Pfizer Plans Workforce Reduction in Switzerland - marketscreener.com
Pfizer Could Claim Tukysa First-Line HER2+ Metastatic Breast Cancer Indication - Citeline News & Insights
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Warning: This Skyrocketing Stock Has a Hidden Risk - The Motley Fool
Pfizer to cut hundreds of jobs in Switzerland by year-end - Investing.com India
Pfizer stock gets Outperform rating from BMO as tucatinib shows promise - Investing.com
Former Pfizer physician challenges RIF, OWBPA disclosures in court - HRD America
Pfizer's Tukysa Combo Shows Strong PFS Benefit In Metastatic Breast Cancer - Benzinga
Pfizer is reportedly shedding hundreds of jobs in Switzerland - Seeking Alpha
Pfizer to cut over 200 jobs in Switzerland to reduce costs, Bloomberg News reports - Reuters
Pfizer Inc. (PFE) announces results from the phase 3 BASIS study evaluating HYMPAVZI - MSN
Pfizer Inc. (PFE) Announces Results from the Phase 3 BASIS Study Evaluating HYMPAVZI - Finviz
Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports - marketscreener.com
Pfizer is cutting hundreds of jobs in Switzerland to lower costsBloomberg News - marketscreener.com
Pfizer Is Cutting Hundreds of Jobs in Switzerland to Lower Costs - Bloomberg.com
Expression Therapeutics Taps Former Pfizer, Novartis Exec as CEO - Contract Pharma
Pfizer’s tucatinib reduces disease progression risk in HER2+ breast cancer By Investing.com - Investing.com Australia
Pfizer Says Metatstatic Breast Cancer Treatment Extends Median Progression-Free Survival - marketscreener.com
PFIZER INC : JP Morgan remains Neutral - marketscreener.com
Pfizer’s tucatinib reduces disease progression risk in HER2+ breast cancer - Investing.com
Pfizer announces results from phase 3 HER2CLIMB-05 trial of Tukysa - marketscreener.com
Pfizer’s Tukysa Slows Breast Cancer When Added to First-Line Care - Bloomberg.com
Fosun's Yao Pharma, Pfizer sign exclusive collaboration dealVietnam Investment Review - Vietnam Investment Review - VIR
HSBC Adjusts Price Target on Pfizer to $29 From $28, Maintains Buy Rating - marketscreener.com
FDA investigating possible adult deaths from COVID-19 vaccines - The Lewiston Tribune
Yao Pharma licenses oral GLP-1R agonists to Pfizer for $1.93 B - BioSpectrum Asia
Pfizer (PFE) Stock: RSV Safety Review Adds Volatility Ahead of Market Open - parameter.io
Pfizer Signs License Deal With Fosun Unit for Obesity Drug - Bloomberg.com
Pfizer partners with YaoPharma to develop weight management drug - Reuters
FDA examines possible adult deaths from Covid-19 shots in probe - The Straits Times
Pfizer Follows $10bn Metsera Purchase By Licensing YaoPharma Obesity Asset - Citeline News & Insights
Down 50%, should you buy the dip on Pfizer? - MSN
Down 50%, Should You Buy the Dip on Pfizer? - Nasdaq
Will Pfizer’s YaoPharma deal deliver a powerful new oral obesity pill? - TradingView
Fosun Pharma's subsidiary Yao Pharma inks deal with Pfizer - The Pharma Letter
Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China - MedCity News
Pfizer Expands Obesity Pipeline With Up to $2.1 Billion Deal for YaoPharma Pill - TradingView
Pfizer signs license deal with Fosun unit for obesity drug - The Detroit News
Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs. - Barron's
Pfizer dips into China for another try at an obesity pill - BioPharma Dive
Eli Lilly's (LLY) Orforglipron Compared to Pfizer's New Collaboration - GuruFocus
Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains (NYSE:PFE) - Seeking Alpha
Pfizer in pact with Fosun Pharma for oral GLP-1s (PFE:NYSE) - Seeking Alpha
Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA - Yahoo Finance
State Street Corp Cuts Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer stock rating reiterated at Buy by Guggenheim on strategic moves - Investing.com Canada
Pfizer Enters Collaboration, License Agreement With YaoPharma for Weight Loss Treatment - marketscreener.com
Pfizer enters $2.1 billion deal with YaoPharma for GLP-1 obesity drug By Investing.com - Investing.com South Africa
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement - The Manila Times
Pfizer enters $2.1 billion deal with YaoPharma for GLP-1 obesity drug - Investing.com Australia
Pfizer (PFE) Secures Global Agreement for GLP-1 Agonist Developm - GuruFocus
Pfizer Inks About $2 Bln Exclusive Deal With Fosun's YaoPharma To For Novel GLP-1 Obesity Therapy - Nasdaq
Pfizer, YaoPharma enter obesity drug collab deal - breakingthenews.net
Pfizer partners with China's YaoPharma for weight loss drug; shares up - TradingView
Pfizer partners with YaoPharma for weight management treatment - marketscreener.com
Pfizer enters into exclusive collaboration and license agreement with Yaopharma - marketscreener.com
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma - Business Wire
Fosun Pharmaceutical says unit signs licensing agreement with Pfizer - marketscreener.com
Pfizer Inc. $PFE Shares Sold by Gabelli Funds LLC - MarketBeat
2 companies poised to capitalize on the rise of GLP-1 drugs - Morningstar Australia
1.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):